玻璃体腔注射雷珠单抗治疗特发性脉络膜新生血管  

Efficacy of intravitreal injection of ranibizumab in treatment of patients with idiopathic choroidal neovascularization

作　　者：杜伟[1] 解正高[1] 朱俊[1] 陈放[1] 

机构地区：[1]江苏省苏北人民医院眼科,江苏扬州225001

出　　处：《实用临床医药杂志》2015年第24期50-52,79,共4页Journal of Clinical Medicine in Practice

摘　　要：目的评价玻璃体腔注射雷珠单抗治疗特发性脉络膜新生血管的疗效。方法对经间接检眼镜、FFA及OCT检查确诊的特发性脉络膜新生血管患者31例(32眼)行玻璃体腔注射雷珠单抗治疗,注射策略为1+PRN,治疗后1 d,2周,1、3个月复查,比较注射前后BCVA(Log MAR视力)、OCT及FFA变化。结果术后1个月BCVA及中心凹视网膜厚度均较注射前有明显改善。FFA检查脉络膜新生血管渗漏明显改善。注射后2例一过性眼压轻度升高以及部分病人有小片结膜下出血,无其他严重并发症。结论玻璃体腔注射雷珠单抗是治疗特发性脉络膜安全、有效的方法。Objective To evaluate the efficacy of intravitreal injection of ranibizumab in the treatment of patients with idiopathic choroidal neovascularization（ ICNV）. Methods A total of 31patients（ 32 eyes） with ICNV diagnosed by indirect ophthalmoscope,FFA and OCT were treated with intravitreal injection of ranibizumab,and the injection strategy was 1 ＋ PRN. Patients were checked 1day,2 weeks,1 month and 3 months after treatment. BCVA、OCT and FFA were compared before and after treatment. Results One month after operation,BCVA and central foveal thickness（ CFT）improved significantly. FFA examination showed that leakage of choroidal neovascularization improved significantly. No severe complications were observed except 2 patients had transient,slightly increased intraocular pressure and a few patients had conjunctive hemorrhage. Conclusion Intravitreal injection of ranibizumab is a safe and effective method for patients with ICNV.

关 键 词：雷珠单抗 特发性脉络膜新生血管 玻璃体腔注射 

分 类 号：R773.4[医药卫生—眼科]